The case for & against
Bull & Bear analysis
Bullish
Eli Lilly and Company (NYSE: LLY) is a leading global pharmaceutical company that specializes in developing and manufacturing innovative medicines across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. As a dominant player in the biopharmaceutical space, Lilly has established a strong market presence through its diverse product portfolio and a commitment to research and development that drives continuous innovation. With an increasing focus on treatments for chronic diseases, particularly diabetes and obesity, Lilly is well-positioned to capitalize on ongoing health trends and demographic shifts.
Bull says
- ↑Q3 revenue $7.7B (+15% YoY) with EPS $1.89 (+12% YoY)
- ↑Diabetes & obesity segment drives >35% of revenue, +20% QoQ sales growth
- ↑$6B R&D spend fuels late-stage Alzheimer and immune therapy pipeline
- ↑Announced $5B buyback with ~3% Buyback Yield LTM, supported by $9B FCF
- ↑Analysts lifting EPS forecasts on strong earnings momentum
- ↑Advanced GLP-1 formulations position Lilly to gain market share
Bear says
- ↓Rising GLP-1 entrants like Novo Nordisk could erode market share
- ↓Premium P/E versus peers leaves limited upside if growth slips
- ↓FDA approval delays or advertising restrictions could hinder sales
- ↓Dependence on diabetes drugs (>35% revenues) risks earnings on setbacks
- ↓Short interest rising and elevated leverage signal growing skepticism
- ↓Biopharma volatility may amplify share price swings in downturns